Sign up Australia
Proactive Investors - Run By Investors For Investors

Medical Cannabis Payment Solutions to accept bitcoin for legal pot purchases using its Green app

“The ability to process bitcoin will make us that much more attractive to marijuana establishments and, perhaps more importantly, their clients,” said CEO Jeremy Roberts
a cannabis plant
Bitcoin goes to pot

Medical Cannabis Payment Solutions (OTC:REFDG) will soon accept bitcoin on its payment-processing platform that services legal marijuana sellers.

The Nevada-based company already processes transactions in US currency nationwide via a payment-processing app called Green. By adding the cryptocurrency to the platform, the company said it hopes to rapidly become “bitcoin-acceptable.”

US credit card companies, such as Visa Inc. (NYSE:V) and Mastercard  Inc. (NYSE:MA) decline to process transactions by state-approved merchants of recreational and medical marijuana, and banks will not accept deposits from pot sellers, even in states where it’s been legalized.

“Traditional banking systems do not allow state-sanctioned marijuana to access their payment systems,” said Jeremy Roberts, CEO of Medical Cannabis Payment Solutions, in a statement. “The feedback we have received indicates that the opportunity is bigger than just cashless electronic payments in US currency.”

Companies of all stripes have been slowly adopting bitcoin payments as the price of the cryptocurrency recently reached mania levels. There’s also been a push among banks and other traditional financial institutions to integrate blockchain the underlying technology behind bitcoin, as a secure option in digital transactions.

“Our security, regulatory compliance and pricing give us a huge competitive advantage,” Roberts said.  “The ability to process bitcoin will make us that much more attractive to marijuana establishments and, perhaps more importantly, their clients.”

 

Join our Crypto, Blockchain and Cannabis Telegram group here
View full APH profile View Profile

Aphria Timeline

Related Articles

woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use